Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-101 in nasolabial fold wrinkles
NCT05162326Phase 1Not yet recruiting
- Sponsor
- Bright Cell, Inc.
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of BC-101 in nasolabial fold rhytides, sponsored by Bright Cell, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BC-101
03
Conditions
nasolabial fold rhytides
Beyond the preview
Go deeper on NCT05162326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162326.